SEC Filing Summary
Issuer and period: The supplied filing is Catalyst Biosciences, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2019 (ticker CBIO), not Gyre Therapeutics, Inc. Investors should confirm the filing matches the intended company.
Business context and reporting period
Catalyst is a clinical-stage biopharmaceutical company developing engineered coagulation factors for hemophilia and other rare bleeding disorders. It had no approved products or product-sale revenue. The financial results cover the three months ended March 31, 2019, compared with the same period in 2018.
Financial performance and liquidity
- Revenue: No contract revenue in Q1 2019, versus $6,000 in Q1 2018.
- Expenses and loss: R&D expense was $12.0 million, up 219%; G&A expense was $3.7 million, up 27%. Total operating expenses were $15.7 million and net loss was $15.1 million, versus $6.7 million of operating expenses and $5.0 million net loss a year earlier. Net loss per share was $1.26, versus $0.56.
- Cash flow: Cash used in operating activities was $15.0 million, compared with $5.1 million in Q1 2018. Investing activities provided $8.7 million, primarily reflecting investment maturities net of purchases. Financing activities provided $0.1 million; Q1 2018 included $111.2 million, primarily from a public offering and warrant exercises.
- Liquidity: Cash, cash equivalents and short-term investments totaled $105.3 million at March 31, 2019, down from $120.1 million at December 31, 2018. Current assets were $109.0 million and current liabilities $4.4 million.
- Debt and other obligations: The filing reports no borrowings on the balance sheet. Operating lease liabilities totaled $2.1 million; the company also had $4.6 million of remaining payment obligations under manufacturing work orders with AGC Biologics.
- Margins: The filing does not provide a meaningful product margin; the company had no product sales and no Q1 2019 revenue.
Material changes versus prior comparable period
- R&D spending rose by $8.3 million, principally from a $6.5 million increase in manufacturing development for MarzAA and DalcA, as well as higher personnel and preclinical research costs.
- Net loss widened by $10.0 million. Interest and other income fell to $0.6 million from $1.6 million, largely because Q1 2018 included a $1.5 million milestone payment related to previously sold assets.
- Cash used in operations increased by $9.9 million. The Q1 2018 comparison also included substantial equity financing that did not recur in Q1 2019.
- Adoption of the new lease standard in January 2019 added approximately $2.1 million in right-of-use assets and lease liabilities, with no reported impact on cash flows or prior financial results.
Outlook, management commentary, risks and contingencies
- Management said existing cash, cash equivalents and short-term investments were expected to fund requirements for at least 12 months from the filing date. The company expects continued losses and higher R&D spending as it advances its programs; management cautioned that its funding assumptions could prove wrong.
- MarzAA: The company reported completed dosing in its Phase 2 open-label SQ efficacy trial. Among seven subjects who completed dosing, reported mean annualized bleed rate declined from 18.2 before treatment to 2.1; five had no bleeds for 50 days at the lowest dose. Management planned to present results for all nine completers in July 2019, start a Phase 1 SQ study in Q2 2019, and initiate a Phase 3 registration study in 2020. These are forward-looking plans, not assured outcomes.
- DalcA: The company reported completed Phase 1/2 SQ dosing, with Factor IX activity levels of 12%–30%; two subjects developed neutralizing antibodies, one transiently. A Phase 2b study was underway, with completion expected in the second half of 2019.
- Additional programs include a Factor IX gene therapy construct, an anti-C3 program for retinal disease, and a Factor Xa candidate. The company had delayed further Factor Xa work and planned a strategic decision on gene therapy development by year-end 2019.
- Funding risks include the possibility that additional financing may be unavailable or unfavorable. Potential equity or convertible-debt financing could dilute shareholders; debt could impose repayment and operating restrictions; collaborations could require relinquishing rights. If funding is insufficient, the company may delay or reduce programs.
- Contingent payments include up to $17.5 million to Pfizer for specified milestones, plus a single-digit royalty on covered product sales if commercialized. The amended ISU Abxis agreement includes up to $19.5 million in milestones and low-single-digit royalties for DalcA sales outside South Korea.
- The company reported no material legal proceedings, no material change to the risk factors in its 2018 Form 10-K, and no off-balance-sheet arrangements. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Confirm the issuer and ticker: the provided filing identifies Catalyst Biosciences (CBIO), not Gyre Therapeutics.
- Check subsequent filings for actual MarzAA and DalcA trial results, timelines, safety findings, and regulatory plans.
- Assess cash burn and runway against current spending plans, financing access, and the manufacturing commitments and contingent milestone obligations.
- Review the original 2018 Form 10-K risk factors and subsequent disclosures for updates to clinical, funding, manufacturing, and collaboration risks.